An Open Label Study of Oral Enzastaurin in Participants With Cancer
Condition: Neoplasms; Cancer
Intervention: enzastaurin
Intervention description: 500 milligrams (mg), oral, daily, six 42-day cycle and subsequent cycles or until participants met study discontinuation criteria of progressive disease or unacceptable toxicity
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 23.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This study will collect further basic safety data on participants with cancer treated with
      enzastaurin. This study is not open to the public.

      The purpose of the this study is to extend the clinical experience of participants who
      complete enzastaurin therapy per clinical pharmacology and biopharmaceutics studies conducted
      by Eli Lilly and Company and who may benefit from continued enzastaurin therapy.
    

Eligibility criteria:

        Inclusion Criteria:

          -  You must have previously participated in and finished Study H6Q-LC-JCAV (JCAV), Study
             H6Q-LC-JCAY (JCAY), or other enzastaurin clinical pharmacology and biopharmaceutics
             studies. If you have had any other cancer treatment (chemotherapy, radiation,
             anti-cancer hormone therapy), you must have completed it at least 4 weeks ago before
             you can enroll in this study.

          -  You must have a cancer for which no other therapy exists that can prolong your life.
             This may include participants with treated, stable brain cancer.

          -  You must have lesions (areas of cancer in your body) that your doctor can either
             measure or detect.

          -  You either must not be able to become pregnant, (because you've had surgery ["tubes
             tied" or hysterectomy], you've gone through menopause, or you've had previous
             radiation for cancer that made you sterile) or your potential to become pregnant must
             be reduced by the use of an approved birth control method (including intrauterine or
             barrier devices) during and for 3 to 6 months following the study.

          -  You can be either male or female, and must be at least 18 years old.

        Exclusion Criteria:

          -  You must not have received treatment within the last 30 days with a drug other than
             enzastaurin that is still experimental (this means it has not received approval to be
             prescribed, except in a clinical trial).

          -  You must not be pregnant or breastfeeding.

          -  You must not have central nervous system (CNS) tumors (tumors in your brain and spinal
             cord). (However, participants who have stable CNS tumors and are taking steroid
             medication may be included.)

          -  You must not have another serious disorder, including active infections that will
             interfere with your participation in the study.

          -  You must not have a second cancer in addition to your primary cancer. Participants
             with adequately treated skin cancer or who have had another cancer in the past, but
             have been cancer free for more than 2 years, are eligible.